Member access

4-Traders Homepage  >  News

News

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesHot NewsMost Read NewsRecomm.Business LeadersVideosCalendar 

Zogenix Inc. : Trading of Zogenix Common Stock Halted

12/07/2012 | 08:00am US/Eastern

FDA Advisory Committee Reviewing Zohydro™ ER New Drug Application

Zogenix to Host Conference Call at 6:30 pm ET Today

SAN DIEGO, Dec. 7, 2012 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, announced that NASDAQ halted trading of the company's common stock on December 7, 2012. The U.S. Food and Drug Administration's (FDA) Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC) is meeting today to review the Company's New Drug Application (NDA) for Zohydro™ ER (hydrocodone bitartrate extended-release capsules).

Conference Call & Webcast

Zogenix will host a conference call to discuss the outcome of the AADPAC meeting today, Friday, December 7, 2012 at 6:30 p.m. ET (3:30 p.m. PT). To participate, please dial (800) 299-9086 (U.S.) or (617) 786-2903 (International); participant passcode: 21970283. To access the live webcast please visit the Zogenix Investor Relations website at http://ir.zogenix.com.  

The conference call will be hosted by Chief Executive Officer Roger L. Hawley and President and Chief Operating Officer Stephen J. Farr, Ph.D.

A replay of the conference call will be available beginning December 7, 2012 at 8:30 p.m. ET (5:30 p.m. PT) until December 14, 2012, by dialing (888) 286-8010 (U.S.) or (617) 801-6888 (International); passcode: 27116437. A replay of the webcast will also be accessible on the Investor Relations website for one month, through January 10, 2013.

About Anesthetic and Analgesic Drug Products Advisory Committee

The AADPAC reviews and evaluates available data concerning the safety and effectiveness of marketed and investigational human anesthetic and analgesic drug products and makes appropriate recommendations to the Commissioner of Food and Drugs. The AADPAC provides FDA with independent expert advice and recommendations, however, the final decision regarding approval is made by FDA.

About Zogenix

Zogenix, Inc., with offices in San Diego and Emeryville, California, is a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain. Zogenix's first commercial product, SUMAVEL® DosePro® (sumatriptan injection) Needle-free Delivery System, was launched in January 2010 for the acute treatment of migraine and cluster headache. Zogenix's lead investigational product candidate, ZohydroTM ER (hydrocodone bitartrate) is an oral, novel extended-release formulation of various strengths of hydrocodone without acetaminophen intended for administration every 12 hours for around the clock management of moderate to severe chronic pain. Zogenix's second DosePro investigational product candidate, ReldayTM, is a proprietary, long-acting injectable formulation of risperidone for the treatment of schizophrenia. In May 2012, Zogenix submitted to the FDA a New Drug Application for Zohydro ER and an Investigational New Drug Application for Relday. The FDA assigned a PDUFA target action date of March 1, 2013 for the Zohydro ER NDA.

For additional information, please visit www.zogenix.com.

SUMAVEL ®, DosePro ®, ReldayTM and ZohydroTM ER are trademarks of Zogenix, Inc.

CONTACT: INVESTORS:
         Zack Kubow | The Ruth Group
         646.536.7020 | zkubow@theruthgroup.com

         MEDIA:
         Emily Poe | WCG
         212.301.7183 | epoe@wcgworld.com
Zogenix
distributed by
React to this article
Latest news
Date Title
02:32a RIO TINTO : Revamps Organisational Structure As Part Of Cost-Cutting Drive
02:32a PREMIER OIL : *exane bnp cuts premier oil price target to 187 (189) pence - 'neutral'
02:32a R STAHL : veröffentlicht vorläufige Ergebnisse des Geschäftsjahres 2014 (DGAP News)
02:32a R STAHL : publishes preliminary results for fiscal year 2014 (DGAP News)
02:32a BEKAERT : and Groz-Beckert reach agreement on the sale of 's Carding Solutions activities
02:31a Year-End Report January–December 2014 CybAero AB (publ)
02:31a MEDIVIR : Financial Statement, January – December 2014
02:31a IXONOS : Loss for the financial year decreased and cash flow improved- strategic direction remains unchanged
02:31a TELESTE : Disposal of own shares based on the performance share program
02:31a IAG upgrades 2015 profit forecast
Latest news
Advertisement
Hot News 
UIL : INVESTOR ALERT: Levi & Korsinsky, LLP Commences an Investigation of the Board of Directors of UIL Holdings corporation In Connection With the Fairness of the Sale of the Company to Iberdrola SA -- UIL
PGT : Nasdaq stocks posting largest percentage increases
RSA INSURANCE : INSURANCE >> giant RSA back in profit
NORTHERN INVESTORS : 27 February 2015 - Tender Offer
CYTORI THERAPEUTICS : Secures Positive European Opinion on Orphan Drug Status
Most Read News
02/26DJCOUNTRY GARDEN : Issues $900 Million, Five-Year Bonds at 7.5%
02/26DJSOUTHWESTERN ENERGY : to Cut Investment Spending
02/26 DEUTSCHE TELEKOM : sees dividend growth in line with free cash flow
02/26 Nissan says can meet U.S. sales goal with capacity in South Korea, Japan
02/26DJWeight Watchers Loses Money, Members -- 2nd Update
Most recommended articles
02/20DJMarkets Hang on Greek Impasse
02:31a IAG upgrades 2015 profit forecast
02:24a PEARSON : posts 5 percent rise in 2014 profit as restructuring ends
02:20a Airbus to cut A330 production rate as ramps up A320
02:19a FT to change the way it charges for digital news
Dynamic quotes  
ON
| OFF